Type III hyperlipoproteinemia (HLP) is mainly found in homozygous apolipoprotein (APO) E2 (R158C) carriers. Genetic factors contributing to the expression of type III HLP were investigated in 113 hyper-and 52 normolipidemic E2/2 subjects, by testing for polymorphisms in APOC3, APOA5, HL (hepatic lipase) and LPL (lipoprotein lipase) genes. In addition, 188 normolipidemic Dutch control panels (NDCP) and 141 hypertriglyceridemic (HTG) patients were genotyped as well. No associations were found for four HL gene polymorphisms and two LPL gene polymorphisms and type III HLP. The frequency of the rare allele of APOC3 3238 G4C and APOA5 À1131 T4C (in linkage disequilibrium) was significantly higher in type III HLP patients when compared with normolipidemic E2/2 subjects, 15.6 vs 6.9% and 15.1 vs 5.8%, respectively, (Po0.05). Furthermore, the frequencies of the APOA5 c.56 G4C polymorphism and LPL c.27 G4A mutation were higher in type III HLP patients, though not significant. Some 58% of the type III HLP patients carried either the APOA5 À1131 T4C, c.56 G4C and/or LPL c.27 G4A mutation as compared to 27% of the normolipidemic APOE2/2 subjects (odds ratio 3.7, 95% confidence interval ¼ 1.8 -7.5, Po0.0001). The HTG patients showed similar allele frequencies of the APOA5, APOC3 and LPL polymorphisms, whereas the NDCP showed similar allele frequencies as the normolipidemic APOE2/2. Patients with the APOC3 3238 G4C/APOA5 À1131 T4C polymorphism showed a more severe hyperlipidemia than patients without this polymorphism. Polymorphisms in lipolysis genes associate with the expression and severity of type III HLP in APOE2/2.
Introduction
Patients with type III hyperlipoproteinemia (HLP) are characterized by elevated levels of total cholesterol and triglycerides (TGs) due to high plasma levels of chylomicron and very low-density lipoprotein (VLDL) remnants enriched in cholesterol esters and apolipoprotein E (APOE). 1, 2 APOE, a major constituent of chylomicron and VLDL remnants, serves as a ligand for the receptor-mediated uptake of these particles by the liver. 3 In type III HLP, APOE mutations lead to an impaired clearance of remnant lipoproteins by hepatic lipoprotein receptors. There are three common genetic variants of APOE: APOE2 (Arg158-Cys), APOE3 (Cys112; Arg158) and APOE4 (Cys112-Arg). These isoforms are encoded by three co-dominant alleles that are located at one single gene locus on chromosome 19 . In comparison to the other two isoforms, APOE2 has less than 1% binding capacity for the hepatic LDL receptor. 4 Most type III HLP patients (490%) are homozygous carriers of APOE2 (Arg158-Cys). 4 In Caucasian populations, APOE2 homozygosity occurs with a frequency of about 1%, whereas the frequency of type III HLP is about 1 -7 per 5000. 5, 6 A minority of the APOE2 homozygous subjects will develop type III HLP, indicating that type III HLP is a multifactorial disorder requiring additional genetic and environmental factors for its clinical manifestation. 4, 7, 8 It has been suggested that contributors to the expression of type III HLP include factors causing (1) an overproduction of lipoproteins, (2) an impaired lipolysis of lipoproteins or (3) an impaired hepatic uptake of remnants. 4, 9 Insulin resistance is associated with high TG levels caused by an increased VLDL production.
10,11
Earlier we found an association of high insulin levels with the expression of type III HLP. 6, 12 Several groups studied genetic factors that may contribute to the expression of type III HLP. 13 -16 However, in the present study, we have studied a larger type III HLP cohort. In addition, we used a normolipidemic APOE2 homozygote cohort as control group. Mutations in genes involved in lipolytic conversion, such as LPL (lipoprotein lipase), HL (hepatic lipase) and APOC3 have been associated with hyperlipidemia (for reviews, see references 17 -20 ). In addition, Zhang et al 13 observed
an increased allele frequency for the LPL N291S mutation in type III HLP patients when compared with the general population. Single nucleotide polymorphisms (SNPs) in the APOA5 gene (11q23) were found to be strongly associated with plasma TG levels. 21, 22 Data from family studies on type III HLP indicate that one or more genes are possible additional genetic factors predisposing to type III HLP. 4 However, from these studies it was not evident which additional genes were involved or whether the study population was very small. In the present study, a significant population of both normolipidemic and hyperlipidemic E2/2 subjects was collected to determine additional genetic risk factors contributing to the expression of type III HLP in APOE2 homozygotes. For comparison, these genetic risk factors were also typed in hypertriglyceridemic (HTG) patients 23, 24 -they partly match their elevated VLDL/TG phenotype with type III HLP patients -and a normolipidemic Dutch control panel (NDCP).
Methods

Subjects
The study population consisted of 167 unrelated homozygous carriers of APOE2 (Arg158-Cys). Type III HLP patients were defined as having total cholesterol and TG levels Z90th percentile, VLDL cholesterol/TG ratio 40.3 (mg/100 ml/mg/100 ml) and/or VLDL cholesterol/VLDL TG ratio of 40.8 (mmol/l/mmol/l), whereas normolipidemic E2/2 subjects had total cholesterol and TG levels o90th percentile according to the age-and sex-related percentile levels of the Prospective Cardiovascular Münster Study (PROCAM). 25 Ultracentrifuge data were not available from 24 HLP type III patients. Two HLP APOE2 homozygotes were excluded from the analysis because their plasma TG levels were normal. In total, 102 type III HLP patients and 9 normolipidemic E2/2 subjects were recruited from the outpatient Lipid Clinics of the University Medical Centers of Leiden, Nijmegen, Amsterdam and Rotterdam. Ten unrelated carriers (two type III HLP patients and eight normolipidemic E2/2 subjects) were detected during a populationbased study among 2018 randomly selected 35-year-old men. 26 In total, 44 E2/2 subjects (9 type III HLP patients and 35 normolipidemic E2/2 subjects) were collected from the Rotterdam Study, a prospective cohort study of 6870 healthy persons aged 55 years and older, investigating determinants of chronic diseases. 27 In this study, we included 113 type III HLP patients and 52 normolipidemic E2/2 subjects. Clinical data and blood samples from type III HLP patients were collected before lipid-lowering medication. One normolipidemic E2/2 subject and one type III HLP patient with a history of pancreatitis were not included in the study.
The selection of the 141 HTG patients was described earlier. 23 The 188 NDCPs were selected on APOE genotype, and total plasma cholesterol, TGs and high-density lipoprotein (HDL) levels, between the 25th and 75th percentile. Informed consent was given by each participant and the study was approved by the Ethics Committee of our hospital. Vascular disease was defined as the presence of coronary artery disease (angina pectoris, 70% stenosis on coronary arteriography, myocardial infarction, coronary by-pass or percutaneous transluminal coronary angioplasty) and/or cerebrovascular disease (stroke or transient ischemic attack) and/or peripheral vascular disease. Hypertension was defined as systolic blood pressure of Z160 mm Hg, or diastolic blood pressure of Z90 mm Hg, or the use of medication for hypertension. 28 Less than 20% of the type III HLP patients were treated with antihypertensive medication: 11% with a betablocker and/or diuretic and 8% with other antihypertensive drugs. About 6% of the normolipidemic subjects were treated with antihypertensive medication. Four patients received antidiabetic medication.
Hyperinsulinemia was defined as fasting insulin concentrations Z100 pmol/l. The diagnostic criterion for diabetes mellitus was fasting blood glucose Z7 mmol/l. Smoking was defined as the consumption of at least 10 cigarettes per day. The non-smokers also included ex-smokers, who stopped smoking for at least 1 year. Alcohol consumers were defined as subjects with alcohol consumption of 2 or more grams per day.
APOE phenotyping and genotyping APOE phenotypes were determined by isoelectric focusing of delipidated serum samples and after cysteamine treatment followed by immunoblotting with a polyclonal anti-APOE antiserum as described. 29 The results were confirmed by APOE genotyping. 
Serum insulin and glucose measurements
Insulin and glucose concentrations were measured only in fasting blood samples. The insulin concentration was determined by a radioimmunoassay (Ins-Ria-100; MedGenix). The antibody of this assay cross-reacts with proinsulin (40%) but not with C-peptide (o0.001%). 32 Serum glucose was determined by the automated hexokinase method of Hitachi 747, Boehringer Mannheim-Hitachi.
DNA analyses
Genomic DNA was isolated from leukocytes. 33 The following mutations or polymorphisms were identified with PCR followed by restriction enzyme analysis as described earlier: the 3238 G4C (Sst-1; rs5128) 34 polymorphism in 3 0 -untranslated region (UTR) of exon 4 of the APOC3 gene, LPL c.27 G4A (D9N; rs1801177), LPL c.1342 C4G (S447X; rs328), 35 LPL c.874 A4G (N291S; rs268), 13 HL c.219 G4A (V73M; rs6078), HL -480 C4T (rs8192701), 36 HL c.1005
A4G (L334F; rs3829462) 37 and HL c.609 C4G (T202T; rs6084) 38 in the LPL and HL genes, respectively. Analysis of both the APOA5 polymorphisms À1131 T4C (SNP3; rs662799) in the APOA5 promoter region and the c.56 G4C (S19W, rs3135506) in exon 3 of the APOA5 gene was as described earlier. 23 
Statistical analyses
Differences between groups were tested with the w 2 test
for dichotomous and categorical variables and the unpaired Student's t-test for continuous variables. As total cholesterol, total TG and plasma insulin levels showed non-Gaussian distributions, these parameters were logarithmically transformed before analysis. Untransformed levels are shown in the tables. For each polymorphism or mutation, the Hardy -Weinberg equilibrium was calculated using the gene-counting method and differences were assessed by the w 2 test. 
Results
Baseline characteristics of the study populations The mean age of type III HLP patients was lower and their BMI was higher compared with normolipidemic E2/2 subjects ( Table 1 ). The prevalence of vascular disease was increased in type III HLP patients, whereas no differences in the occurrence of hypertension, diabetes mellitus and the number of smokers and alcohol consumers were found between the groups. Furthermore, type III HLP patients had significantly higher total TG and insulin levels as compared with normolipidemic E2/2 subjects, whereas HDL cholesterol was decreased. Characteristics of the normolipidemic panel (NDCP) and HTG patients are summarized in Table 1 . Table 2 shows the genotype distributions and allele frequencies of polymorphisms in the APOC3, APOA5 and LPL genes in the type III HLP patients, normolipidemic E2/ 2 subjects, NDCP and the HTG patients. The genotype or allele frequencies of all HL polymorphisms and a subset of the analyzed LPL polymorphisms did not differ significantly between the study populations and are not shown in Table 2 . These include: HL À480 C4T, HL c.219 G4A, HL c.1005 A4G, HL c.609 C4G, LPL c.874 A4G and LPL c.1342 C4G. All polymorphisms, in all groups, were in Hardy -Weinberg equilibrium. Distribution of the genotypes of the APOC3 3238 G4C, APOA5 À1131 T4C and LPL c.27 G4A polymorphisms differed significantly between the normolipidemic E2/2 subjects and the type III HLP patients (Table 2) . Distribution of the genotypes of the APOC3 3238 G4C, APOA5 À1131 T4C and LPL c.27 G4A, but not the APOA5 c.56 G4C polymorphisms, differed significantly between NDCP and type III HLP patients. We observed a significant difference in genotype frequency between HTG patients and type III HLP patients for the APOA5 À1131 T4C polymorphisms but we did not observe such difference for the APOC3 3238 G4C, APOA5 c.56 G4C and LPL c.27 G4A polymorphisms.
Genotype and allele frequencies
The frequency of the minor allele of the APOC3 3238 G4C polymorphism and the (in LD) APOA5 À1131 T4C polymorphism was increased in type III HLP patients and the HTG patients (15.6 and 15.1% in the type III HLP, 21.7 and 23.5% in the HTG patients, vs a mean NDCP/ normolipidemic APOE2 homozygotes of B7.2 and B6.1%, respectively). The APOA5 c.56 G4C polymorphism showed a significantly increased frequency of the minor allele in type III HLP patients (11.8%) and in HTG patients (18.7%) when compared with the mean minor allele frequency of the NDCP/normolipidemic APOE2 homozygotes (B6.2%). A significant enrichment of the minor allele of the LPL c.27 G4A mutation was observed among type III HLP patients (6.2%) as compared to the other study populations (NDCP and normolipidemic APOE2 homozygotes, 2.6 and 1.0%, respectively). LD estimation within the tightly linked cluster of the APOC3/A5 region confirmed earlier findings of others that the APOA5 À1131 T4C and APOC3 3238 G4C polymorphisms are in strong LD (D 0 ¼ 0.8), whereas the APOA5 c.56 G4C and À1131 T4C polymorphisms are not.
Association of APOC3 3238 G4C, APOA5 À1131 T4C, APOA5 c.56 G4C and LPL c.27 G4A with type III HLP Association between polymorphisms and the expression of type III HLP was tested by logistic regression analysis using a dominant model (ie, 1/1 vs 1/2 þ 2/2). Table 3 shows the association of the APOC3 3238 G4C polymorphism (OR ¼ 2.7, 95% CI 1.1 -6.7, P ¼ 0.03), the APOA5 À1131 T4C polymorphisms (OR ¼ 3.1, 95% CI 1.2 -8.0, P ¼ 0.02), the APOA5 c.56 G4C polymorphism (OR ¼ 2.4, 95% CI 0.9 -6.7, P ¼ 0.12) and the LPL c.27 G4A mutation (OR ¼ 6.6, 95% CI 0.8 -52.1, P ¼ 0.07) with the occurrence of type III HLP.
The APOA5 À1131 T4C and APOC3 3238 G4C polymorphisms (in LD) showed a similar significantly increased risk on the occurrence of type III HLP. A significant association between the APOA5 c.56 G4C polymorphism and the LPL c.27 G4A mutation and expression of type III HLP was not seen. However, the association (Table 3 , cumulative) of carrying a rare allele of either APOA5 c.56 G4C, À1131 T4C, APOC3 3238 G4C polymorphisms or LPL c.27 G4A mutation (OR ¼ 3.7, 95% CI 1.8 -7.5, Po0.0001) and the expression of type III HLP was significantly increased.
To investigate the effect of the polymorphisms on plasma lipid levels, type III HLP patients were divided into Lipolysis genes in type III hyperlipoproteinemia P Henneman et al carriers and non-carriers of the polymorphisms. Type III HLP patients with the APOC3 3238 G4C polymorphism and (in LD) the APOA5 À1131 T4C polymorphism showed increased levels of total cholesterol as compared with their counterparts without the polymorphism (Figure 1 ). Total TG levels were significantly increased in carriers of the APOA5 À1131 T4C polymorphism as compared with noncarriers, whereas the increased levels of total TG levels in the APOC3 3238 G4C carriers did not reach statistical significance (Figure 2 ). To further determine the association of the different cholesterol-rich lipoprotein fractions with genetic variation, we also investigated the effect of the polymorphisms, APOC3 3238 G4C, APOA5 À1131 T4C and c.56 G4C, and LPL c.27 G4A on plasma HDL cholesterol and VLDL cholesterol ( Figure 3) . We observed no effect of the polymorphisms on plasma HDL cholesterol (data not shown), whereas carriers of rare variants of both APOC3 3238 G4C and APOA5 À1131 T4C showed a significant association with plasma VLDL cholesterol levels. Evaluation of the association of the APOA5 c.56 G4C, APOA5 À1131 T4C, APOC3 3238 G4C and the LPL c.27 G4A variants with plasma lipid levels in the NDCP did not reveal any significant associations. The effect of the polymorphisms on lipid levels in the HTG patients has been described earlier.
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Discussion
The clinical manifestation of type III HLP, in addition to defective hepatic clearance of remnant lipoproteins in E2/2 subjects, may be caused by impaired lipolysis. 4, 9, 40 Several groups reported about LPL and proteins involved in LPL activity, as apoCIII and apoAV in type III patients. 13 -16 In accordance with this hypothesis, we replicated in the largest type III cohort thus far, associations for polymorphisms in proteins involved in the lipolysis of lipoproteins: the 3238 G4C polymorphism in the APOC3 gene (in LD Lipolysis genes in type III hyperlipoproteinemia P Henneman et al with APOA5 À1131 T4C polymorphism) and the c.27 G4A mutation in the LPL gene. Our results show that the APOC3 3238 G4C/APOA5 À1131 T4C polymorphism exacerbates the hyperlipidemic phenotype of type III HLP patients, whereas the LPL c.27 G4A mutation has no additional effect on plasma lipid levels.
In an earlier study, we found an interaction between hyperinsulinemia and the APOC3 3238 G4C polymorphism, associated with severe hyperlipidemia in APOE2 homozygotes. 12 By increasing the number of E2/2 subjects, data from the present study demonstrate that the APOC3 3238 G4C polymorphism per se is also an important contributor to type III HLP expression. The APOC3 3238 G4C polymorphism is strongly associated with elevated plasma TG levels. 41 In accordance, our type III HLP patients carrying the APOC3 3238 G4C polymorphism showed a more severe hyperlipidemia, ie higher VLDL cholesterol levels and a tendency of higher TG levels than non-carriers. The molecular mechanism underlying the association with HTG is still unclear. The APOC3 3238 G4C polymorphism is located in the 3 0 -UTR of the APOC3 gene and could be a causal variant by acting on mRNA stability, which results in increasing apoCIII plasma levels. However, it is also possible that the APOC3 3238 G4C polymorphism itself is not responsible for the TG-raising effect. Other mutations within the APOA1-C3-A4 gene cluster, located near the APOC3 3238 G4C polymorphic site, could be candidates for being the causative mutations Type III HLP: type III hyperlipidemic patients; normo: normolipidemic E2/2 subjects; OR: odds ratio; 95% CI: 95% confidence interval; 1/1, homozygous for the common allele; 1/2 heterozygous for the common and rare allele; 2/2, homozygous for the rare allele; cumulative f: non-carrier represents non-carrier of the rare allele of either the APOA5 c.56 G4C, SNP3, APOC3 À1131 T4C or LPL c.27 G4A and carrier represents carrier of the rare allele of either the APOA5 c.56 G4C, SNP3, APOC3 À1131 T4C or LPL c.27 G4A. Lipolysis genes in type III hyperlipoproteinemia P Henneman et al leading to HTG. Two polymorphisms located at positions À482 and À455 in the promoter region of the APOC3 gene showed substantial LD with the 3238 G4C polymorphism, as reported by others. 41 -43 However, we found in a much smaller subgroup of our type III HLP patients, no evidence of an association between these polymorphisms and increased TG levels, 12 whereas Miller et al 40 suggested an association with these two APOC3 polymorphisms and the metabolic syndrome. Functional studies to elucidate the exact role on apoCIII protein levels of each of these three polymorphisms should be performed. The LPL c.27 G4A mutation leads to an increased bridging of LDL and monocyte adhesion and is also associated with elevated levels of plasma TGs and reduced plasma HDL cholesterol levels. 44 In our type III HLP patients, a tendency toward increased plasma cholesterol and TG levels was observed in LPL c.27 G4A carriers, but this did not reach statistical significance, possibly due to the size of our groups. In Caucasians, the -93T-G transition in the LPL gene promoter is in LD with the LPL c.27 G4A mutation. 18, 45 However, several studies have reported that the TG-raising effect was solely attributable to the presence of the LPL c.27 G4A mutation. 45 Data from genetic association studies on type III HLP are limited due to the low prevalence of APOE2 homozygosity in the population. To circumvent this problem, most studies have compared the allele frequency of mutations in type III HLP patients with that of the general population. Zhang et al 13 found an increased allele frequency for the LPL N291S mutation in type III HLP patients as compared with the Dutch population. However, this approach does not include the possibility that the mutation is also more prevalent in normolipidemic APOE2 homozygotes. Conversely, Evans and Beil 16 showed that the LPL mutations D9N, in particular N291S and S447X (c.27 G4A, c.874 A4G and c.1342 C4G, respectively), were not associated with type III HLP.
Comparison of the Dutch population frequency for the HL À480 C4T mutation (19%) with that of our type III HLP patients (31%) revealed that the mutation was more prevalent in patients (Po0.001). 36 As we did not find such a difference between patients and normolipidemic E2/2 subjects, we may conclude that the LPL c.874 A4G and the HL À480 C4T mutations are not major contributors to the expression of type III HLP (data not shown). In addition, no association with type III HLP was found for HL c.219 G4A, 1005 A4G, 609 C4G and LPL c.1342 C4G.
To further study the patient and population prevalences of the APOA5, APOC3 polymorphisms and the LPL c.27 G4A mutation, two additional populations were screened: the NDCP and HTG patients. The prevalences of the APOC3 3238 G4C/APOA5 À1131 T4C polymorphism, APOA5 c.56 G4C and the LPL c.27 G4A mutation in the NDCP cohort are similar to those observed in the normolipidemic APOE2 homozygote individuals. This indicates that the normolipidemic APOE2 homozygotes were not a selected sub-population. In contrast, the prevalences of the APOC3, APOAV and LPL mutations in the HTG patients are similar to those of the type III patients, indicating that these polymorphisms are universal risk factors for HTG.
Earlier studies have reported frequencies for the rare variant of the c.56 G4C polymorphism in type III patients. 14, 15, 46 In our type III patients, the rare variant of the APOA5 c.56 G4C polymorphism is far less frequent (11.8%) than reported thus far. In addition, 4.9% of the normolipidemic APOE2 homozygotes still was carrier of the rare allele of the APOA5 c.56 G4C polymorphism. Moreover, we found no association between plasma TG and cholesterol levels and the c.56 G4C polymorphism in hyper-and normolipidemic FDs. The fact that this association is not present and the frequency of the c.56 C-allele is somewhat increased in the type III HLP population suggests that the APOA5 c.56 G4C polymorphism is a weak contributor to the clinical manifestation of type III HLP. The mechanism by which this variant acts remains to be solved. It has been suggested that the APOA5 c.56 G4C polymorphism alters the signal peptide, which results in a decreased secretion of apoAV protein. However, such correlation between APOA5 rare variant carriers and plasma apoAV was not found in a cohort of HTG patients. 23 As reported by others, our data show that the APOC3 3238 G4C and APOA5 À1131 T4C polymorphisms show a high LD. 41, 47 In total, 15% of type III HLP patients are carriers of the APOA5 À1131 T4C polymorphism and 15.6% are carriers of the APOC3 3238 G4C polymorphism.
In the present study, we did not aim to elucidate a causal role of each polymorphism.
In total, 58% of type III HLP patients vs 27% of normolipidemic APOE2 homozygotes are carriers of the APOC3 3238 G4C/APOA5 À1131 T4C polymorphism, APOA5 c.56 G4C and/or the LPL c.27 G4A mutation, Figure 3 Effect of the APOC3 3238 G4C, the APOA5 À1131 T4C
and APOA5 c.56 G4C, and the LPL c.27 G4A polymorphisms on VLDL-cholesterol levels in type III HLP patients. N represents number of type III HLP patients. *Po0.05.
indicating that these mutations could partly explain the expression of type III HLP. Additional genetic and environmental risk factors remain to be identified. Earlier, we found that hyperinsulinemic APOE2 homozygotes have an increased risk for type III HLP. 6 It is likely that the suppression of VLDL production by insulin in these hyperinsulinemic patients is reduced, resulting in chronically elevated VLDL production. 10 Another possible mechanism is through an interaction between insulin and genes involved in the lipolysis of lipoproteins. Several studies support the hypothesis that insulin is involved in the regulation of the APOC3 gene. The presence of the APOC3 -455 and -482 polymorphisms may abolish the insulin responsiveness of the APOC3 promoter. 48, 49 As the APOC3 3238 G4C polymorphism in E2/2 subjects is almost exclusively found in combination with the presence of the -455 and -482 promoter variants, it seems possible that in E2/2 subjects, who are carriers of the 3238 G4C polymorphism, the loss of insulin regulation results in overexpression of the APOC3 gene and, as a consequence, in overt hyperlipidemia. 12, 34 In addition, insulin is a major regulator of LPL activity. The combination of high insulin levels and decreased LPL activity, as found in carriers of LPL mutations, may further exacerbate the expression of HTG. 50 In conclusion, our data indicate that the APOC3 3238 G4C, APOA5 À1131 T4C and, to a lesser extent, LPL c.27 G4A mutation associate with a more severe hyperlipidemia in type III patients, whereas APOA5 c.56 G4C is perhaps a weak modifier.
